Sartorius stock gains as Berenberg raises price target to 280 euros
Published on 09/11/2026 at 15:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sartorius AG stock (ISIN DE0006292006) is trading around EUR 231.10 on Xetra as of September 11, 2026, leaving the shares below recent analyst targets but supported by solid full-year 2025 figures and fresh positive research commentary.
Analyst upgrade supports Sartorius stock
The most important catalyst for Sartorius stock on September 11, 2026 is a new research note from private bank Berenberg, which has raised its price target for the shares to EUR 280 from EUR 270 while reiterating a Buy rating.Boerse Online According to the dpa-AFX flash cited in the note, analyst Sam England argues that the medical technology and life sciences sector remains fundamentally attractive, highlighting Sartorius among a group of companies he sees as well positioned.Zonebourse
As summarized by financial portal MarketScreener, Berenberg advises its clients to buy Sartorius stock and now sees fair value at EUR 280 per share compared with the previous target of EUR 270, implying an increase of EUR 10 or about 3.7 percent in the bank's valuation benchmark.MarketScreener Compared with the latest Xetra close of EUR 230.90 on September 10, 2026, the new Berenberg target of EUR 280 represents upside of around EUR 49.10 per share, or roughly 21.3 percent, underlining the bank's constructive stance on the stock.Zonebourse
Price level and trading range on Xetra
On the market side, Sartorius AG shares most recently closed at EUR 230.90 on Xetra on September 10, 2026, with the session showing a decline of 2.49 percent from the prior day and a closing level that remains within the established 52-week trading band.Zonebourse An intraday price snapshot from MarketScreener on September 11, 2026 showed Sartorius quoted around EUR 230.50, down 0.52 percent on the day and modestly lower than the latest close.MarketScreener
Separate Xetra price data compiled by Yahoo Finance show Sartorius trading at EUR 186.80 at 1:02 p.m. Central European time with a daily gain of 1.74 percent, a previous close of EUR 183.60 and a 52-week low of EUR 68.75.Yahoo Finance In that quote overview, the current price lies far above the 52-week low and below the 52-week high region around EUR 249.53, illustrating that the shares have already recovered substantially from their lows while still trading at a discount to their peak levels in the current year.Yahoo Finance
Latest full-year figures highlight scale and margins
For investors assessing Sartorius stock, the latest available full-year figures for fiscal 2025 provide important context for the Berenberg upgrade and the current valuation. According to an SEC filing by Bio-Rad Laboratories, which reports on its stake in Sartorius using data from Sartorius' audited IFRS financial statements, Sartorius generated sales revenue of EUR 3,538.1 million in the year ended December 31, 2025.Stock Titan Compared with the company's historical revenue levels reported for earlier years, this 2025 revenue figure underscores Sartorius' position as a multi-billion-euro player in bioprocess solutions and laboratory products.
In the same full-year 2025 statement, Sartorius reported gross profit of EUR 1,636.7 million and earnings before interest and taxes (EBIT) of EUR 542.6 million, indicating an EBIT margin of around 15.3 percent on sales revenue.Stock Titan Net profit attributed to Sartorius for fiscal 2025 stood at EUR 230.4 million, while cash flow from operating activities reached EUR 837.0 million, illustrating the company's ability to translate its revenue base into significant operating cash generation.Stock Titan
Analyst consensus and valuation backdrop
Beyond the Berenberg upgrade, broader analyst consensus data collected by MarketScreener show that 20 analysts currently cover Sartorius AG, with a mean recommendation of Outperform as of September 11, 2026.MarketScreener The average target price in this consensus stands at EUR 271.21, compared with the latest Xetra close of EUR 230.90, implying potential upside of about 17.5 percent if the shares were to move toward the mean target.Zonebourse
Within that range of estimates, the highest price target identified by MarketScreener is EUR 307.00 per share and the lowest is EUR 190.00, giving a spread of 32.96 percent above and 17.71 percent below the latest close respectively.MarketScreener For investors, this dispersion illustrates both the perceived long-term growth potential in Sartorius' markets and the risks around execution and cyclicality: optimistic analysts expect the stock to climb well above current levels, while more cautious voices see limited upside or even downside relative to today's price.
Sector backdrop and key risks
In its sector commentary, Berenberg emphasizes that medical technology and life sciences companies such as Sartorius benefit from structurally attractive demand trends, supported by ongoing investments in biopharmaceutical production, cell and gene therapies, and advanced laboratory research infrastructure.Zonebourse However, the same analysis also implicitly points to risks for Sartorius stock, including sensitivity to capital expenditure cycles in the biopharma industry, potential delays in customer investment decisions and regulatory changes that could affect demand for certain technologies.
Recent trading patterns around the September 10, 2026 Xetra session show that Sartorius can underperform German equity indices on individual days even when the broader market is described as little changed, underlining the stock's exposure to company-specific news and sentiment rather than purely index movements.Ad hoc news For long-term holders, the combination of solid 2025 fundamentals, positive operating cash flow and constructive analyst coverage provides a supportive backdrop, but the share price remains subject to volatility as expectations for growth and margins are adjusted with each new data point.
Stock trades below key analyst targets
At the latest Xetra close of EUR 230.90 on September 10, 2026, Sartorius stock trades clearly below the new Berenberg target of EUR 280 and the analyst consensus average of EUR 271.21, leaving a notable gap between current market pricing and the valuations implied by recent research.Zonebourse As of September 11, 2026, a Tradegate quote compiled by Zonebourse shows the shares at EUR 231.10 with a daily gain of 0.52 percent and a year-to-date decline of 4.80 percent, suggesting that the stock has still not fully recovered from earlier weakness in 2026.Zonebourse
Sartorius AG stock facts
- Company: Sartorius AG
- ISIN: DE0006292006
- Ticker: SRT
- Trading venue: Xetra
- Price (as of September 11, 2026, 11:45): 231.10 EUR
- Market capitalization: 12,678,000,000 EUR (as of September 10, 2026)
- Sector / Industry: Health care equipment and life sciences tools
- Index membership: MDAX
